Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109532305 | 10953230 | 5 | F | 20160901 | 20150325 | 20160907 | EXP | JP-SA-2015SA035905 | AVENTIS | NISHIHAMA K, MAKI K, OKANO Y, HASHIMOTO R, HOTTA Y, UEMURA M ET AL. A CASE OF TYPE 2 DIABETES MELLITUS WITH METFORMIN-ASSOCIATED LACTIC ACIDOSIS INITIALLY PRESENTING THE APPEARANCE OF A SULFONYLUREA-RELATED HYPOGLYCEMIC ATTACK. ACUTE MEDICINE AND SURGERY 2016. DOI: 10.1002/AMS2.233 | 64.00 | YR | A | F | Y | 77.20000 | KG | 20160907 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109532305 | 10953230 | 1 | PS | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | Oral | U | UNK | 20496 | 1 | MG | QD | ||||||
| 109532305 | 10953230 | 2 | SS | VOGLIBOSE | VOGLIBOSE | 1 | Oral | U | UNK | 0 | .9 | MG | QD | ||||||
| 109532305 | 10953230 | 3 | SS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | U | UNK | 0 | 2250 | MG | QD | ||||||
| 109532305 | 10953230 | 4 | SS | CANDESARTAN CILEXETIL. | CANDESARTAN CILEXETIL | 1 | Unknown | U | UNK | 0 | 8 | MG | QD | ||||||
| 109532305 | 10953230 | 5 | SS | OLMESARTAN | OLMESARTAN | 1 | Unknown | U | UNK | 0 | 20 | MG | QD | ||||||
| 109532305 | 10953230 | 6 | C | EXENATIDE | EXENATIDE | 1 | 0 | 20 | UG | QD | |||||||||
| 109532305 | 10953230 | 7 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | 5 | MG | QD | |||||||||
| 109532305 | 10953230 | 8 | C | ROSUVASTATIN. | ROSUVASTATIN | 1 | 0 | 2.5 | MG | QD | |||||||||
| 109532305 | 10953230 | 9 | C | TOCOPHEROL | TOCOPHEROL | 1 | 0 | 600 | MG | QD | |||||||||
| 109532305 | 10953230 | 10 | C | POLAPREZINC | POLAPREZINC | 1 | 0 | 150 | MG | QD | |||||||||
| 109532305 | 10953230 | 11 | C | CEFTRIAXONE. | CEFTRIAXONE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 109532305 | 10953230 | 1 | Type 2 diabetes mellitus |
| 109532305 | 10953230 | 2 | Type 2 diabetes mellitus |
| 109532305 | 10953230 | 3 | Type 2 diabetes mellitus |
| 109532305 | 10953230 | 4 | Hypertension |
| 109532305 | 10953230 | 5 | Hypertension |
| 109532305 | 10953230 | 6 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 109532305 | 10953230 | HO |
| 109532305 | 10953230 | LT |
| 109532305 | 10953230 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 109532305 | 10953230 | Acute kidney injury | |
| 109532305 | 10953230 | Anion gap increased | |
| 109532305 | 10953230 | Base excess decreased | |
| 109532305 | 10953230 | Blood bicarbonate decreased | |
| 109532305 | 10953230 | Blood creatinine increased | |
| 109532305 | 10953230 | Blood lactic acid increased | |
| 109532305 | 10953230 | Blood pH decreased | |
| 109532305 | 10953230 | Blood urea increased | |
| 109532305 | 10953230 | Blood uric acid increased | |
| 109532305 | 10953230 | C-reactive protein increased | |
| 109532305 | 10953230 | Condition aggravated | |
| 109532305 | 10953230 | Costovertebral angle tenderness | |
| 109532305 | 10953230 | Decreased appetite | |
| 109532305 | 10953230 | Dehydration | |
| 109532305 | 10953230 | Drug level increased | |
| 109532305 | 10953230 | Fatigue | |
| 109532305 | 10953230 | Hypoglycaemia | |
| 109532305 | 10953230 | Lactic acidosis | |
| 109532305 | 10953230 | Metabolic acidosis | |
| 109532305 | 10953230 | Oedema peripheral | |
| 109532305 | 10953230 | PO2 decreased | |
| 109532305 | 10953230 | Peripheral circulatory failure | |
| 109532305 | 10953230 | Renal impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |